Cardiff Oncology, Inc.
CRDF· Nasdaq
CRDFCardiff Oncology, Inc.
Filed Nov 14, 2012 · 10-Q · 45 days after period end · 0001104659-12-077744
| Metric | Q3 2012 | Q3 2011 |
|---|---|---|
| Revenue | $212.00K | $55.00K |
| Net Income | -$650.23K | $9.27K |
| EPS Diluted | -$0.05 | $0.00 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
ended Sep 30, 2012 · filed Nov 14, 2012 · 45 d after period end
